Title: Pretargeted radioimmunotherapy with Bi-213 in mice with CEA-expressing colon cancer xenografts
Authors: HESKAMP SandraHERNANDEZ ReinierESSLER MarkusBRUCHERTSEIFER FrankMORGENSTERN AlfredOYEN WimSEIDL C.MCBRIDE WilliamGOLDENBERG DavidBOERMAN Otto
Citation: JOURNAL OF NUCLEAR MEDICINE vol. 56 no. S3 p. 9
Publisher: SOC NUCLEAR MEDICINE INC
Publication Year: 2015
JRC N°: JRC94668
ISSN: 0161-5505
URI: http://jnm.snmjournals.org/content/56/supplement_3.toc
http://publications.jrc.ec.europa.eu/repository/handle/JRC94668
Type: Articles in periodicals and books
Abstract: Pretargeted radioimmunotherapy (PRIT) with TF2, an anti-CEA x anti-HSG bispecific antibody, and 177Lu-labeled di-HSG-DOTA peptide IMP288, can delay tumor growth of CEA-expressing colon cancer xenografts. The therapeutic efficacy of PRIT may be improved by using alpha-emitting radionuclides. The aim of this study was to assess the potential of 213Bi for PRIT.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.